These states are national leaders when it comes to driving 21st century forward. Today, we're looking at tech leaders across ...

If chivalry isn't already dead, it's certainly circling the drain. OpenAI CEO and tech billionaire Sam Altman recently ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Spotify appeared to be experiencing a widespread technical issues Wednesday morning — with tens of thousands of users ...

President Trump unveiled a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged ...

Mayoral candidate Scott Stringer is proposing a new zoning designation to block President Donald Trump from auctioning off federal buildings to luxury developers, the Daily News has ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer. The infused treatment from Japanese drugmaker Eisai and ...

Shares of Biogen Inc. BIIB slipped 4.31% to $114.05 Tuesday, on what proved to be an all-around poor trading session for the ...

Biogen Inc. has a one year low of $122.77 and a one year high of $238.00. The company has a market cap of $18.00 billion, a PE ratio of 10.99, a P/E/G ratio of 1.51 and a beta of 0.01.

During the last three months, 14 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their ...

Brain health has emerged as one of the defining challenges of our time, driven by a double whammy of soaring rates of ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...